– USA, CA – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Steve Krognes to its board of directors.
“We are very pleased to welcome Steve Krognes to our board of directors. With over 20 years in the biotech and life science industry, Steve brings a wealth of knowledge and expertise in financial management and corporate strategy. These insights will be extremely valuable as we continue to shape the company’s next chapters,” said chairman and co-CEO, Helmy Eltoukhy.
About Steve E. Krognes
Steve Krognes is a professional independent board member in the biotech and life science sector. He currently serves as a director at Denali Therapeutics Inc., Gritstone bio, Inc., and RLS Global AB, and previously served on the board at Corvus Pharmaceuticals, Inc.
Before becoming a board member of the company, Mr. Krognes was CFO of Denali Therapeutics. In this role, he led the company’s IPO efforts and built the corporate finance, information technology, and site organizations to enable the company to reach a greater scale. Before Denali, he served in a variety of roles at large multinational corporations, including CFO at Genentech, Inc. where he led the integration of Genentech and Roche Holding AG in the U.S. and the integration of Genentech and InterMune, Inc. He chaired the Genentech Access to Care Foundation and represented Genentech on the board and executive committee of the California Life Science Association. Before Genentech, Mr. Krognes was the global head of mergers and acquisitions at Roche. He also worked as an investment banker at Goldman Sachs, as a management consultant at McKinsey & Company, and as a venture capitalist in Scandinavia.
Mr. Krognes holds a Master of Business Administration from Harvard Business School and a Bachelor of Science in Economics from the Wharton School of the University of Pennsylvania.
About Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through the use of its proprietary tests, vast data sets, and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes, and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360, Guardant360 CDx, Guardant360 TissueNext, Guardant360 Response, and GuardantOMNI tests for advanced-stage cancer patients, and Guardant Reveal for early-stage cancer patients. The Guardant Health screening portfolio, including the commercially launched Shield test, aims to address the needs of individuals eligible for cancer screening.
For more information : https://guardanthealth.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.